Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (353)	4/1/2002 12:09:40 AM
From: Londo	Respond to of 557

OT.. a little humour for the end of the weekend. So, when Xcyte has its IPO, you can be sure I wont be helping to ensure the VCs get a return on their investment. Fool me twice! Since their corporate logo looks like the one of Lucent Technologies, maybe you'll get your wish when investors believe that the future performance of the stock will be just like them. Seriously, compare: lucent.com xcyte.com Maybe XCyte might get sued for trademark dilution as well? I remember when goto.com successfully sued Infoseek (or the GO network, or whatever the heck they called themselves) for having a traffic-light logo that looked pretty similar.

To: Mike McFarland who wrote (353)	4/1/2002 3:49:29 AM
From: Michael Bakunin	Read Replies (2) \| Respond to of 557

> With a lot of biotech valuations in the > toilet, the average shareholder in something > like Tgen, has got to be feeling like a sucker. ..and yet those valuations have me interested in the group again. I picked up some TGEN at 2 last week; the purchase may yet have me feel like a sucker, but at least not 'til trading starts tomorrow.. -g- Aside from my feeling that, in the long run, TGEN's a nice lottery ticket to own in this space, I appreciate the promotion that management has been doing. Throw in some fingers-crossed data coming out this year and I hope not to feel too foolish about my purchase come fall. As for CellExSys, their plan is to sell equity stakes to keep it funded (cf the 10-K; "Upon completion of these funding activities, we would no longer be the majority owner"). Management assures us TGEN is funded through 2004, so they'd better be getting cash somewhere. I hope biotech stays in the dumps for another month, since I still have shopping to do for my portfolio. -mb